JP2013501071A5 - - Google Patents

Download PDF

Info

Publication number
JP2013501071A5
JP2013501071A5 JP2012523941A JP2012523941A JP2013501071A5 JP 2013501071 A5 JP2013501071 A5 JP 2013501071A5 JP 2012523941 A JP2012523941 A JP 2012523941A JP 2012523941 A JP2012523941 A JP 2012523941A JP 2013501071 A5 JP2013501071 A5 JP 2013501071A5
Authority
JP
Japan
Prior art keywords
composition
stabilizing amount
linaclotide
item
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012523941A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013501071A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/044522 external-priority patent/WO2011017502A2/en
Publication of JP2013501071A publication Critical patent/JP2013501071A/ja
Publication of JP2013501071A5 publication Critical patent/JP2013501071A5/ja
Withdrawn legal-status Critical Current

Links

JP2012523941A 2009-08-06 2010-08-05 リナクロチドを含む処方物 Withdrawn JP2013501071A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23172509P 2009-08-06 2009-08-06
US61/231,725 2009-08-06
PCT/US2010/044522 WO2011017502A2 (en) 2009-08-06 2010-08-05 Linaclotide-containing formulations for oral administration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015025192A Division JP2015098476A (ja) 2009-08-06 2015-02-12 リナクロチドを含む処方物

Publications (2)

Publication Number Publication Date
JP2013501071A JP2013501071A (ja) 2013-01-10
JP2013501071A5 true JP2013501071A5 (https=) 2013-09-12

Family

ID=43544939

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012523941A Withdrawn JP2013501071A (ja) 2009-08-06 2010-08-05 リナクロチドを含む処方物
JP2015025192A Pending JP2015098476A (ja) 2009-08-06 2015-02-12 リナクロチドを含む処方物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015025192A Pending JP2015098476A (ja) 2009-08-06 2015-02-12 リナクロチドを含む処方物

Country Status (5)

Country Link
US (4) US8748573B2 (https=)
JP (2) JP2013501071A (https=)
CA (1) CA2770077A1 (https=)
MX (2) MX2012001660A (https=)
WO (1) WO2011017502A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117530912A (zh) 2008-08-15 2024-02-09 硬木药品公司 适合口服给药的鸟苷酸环化酶-c受体激动剂多肽的稳定的固体制剂
CA2770077A1 (en) 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
US8933030B2 (en) 2010-02-17 2015-01-13 Ironwwod Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
DK2603232T3 (da) * 2010-08-11 2019-12-09 Ironwood Pharmaceuticals Inc Stabile formuleringer af linaclotid
US9708371B2 (en) * 2011-08-17 2017-07-18 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
JP2016521249A (ja) * 2012-07-12 2016-07-21 フォレスト ラボラトリーズ ホールディングス リミテッド リナクロチド組成物
UA119335C2 (uk) * 2013-12-11 2019-06-10 Айронвуд Фармасьютикалз, Інк. Композиції лінаклотиду з затриманим вивільненням
WO2015166468A1 (en) * 2014-05-02 2015-11-05 Sinoveda Canada, Inc. Formulas comprising highly soluble elements and vitamin d for the prevention and treatment of bowel conditions during calcium supplementation
WO2016024291A1 (en) 2014-08-11 2016-02-18 Sun Pharmaceutical Industries Ltd. Linaclotide stable composition
US11572386B2 (en) * 2014-09-08 2023-02-07 Auro Peptides Ltd. Process for the preparation of linaclotide
DK3006045T3 (en) * 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
US20180008547A1 (en) * 2015-02-02 2018-01-11 Aurobindo Pharma Ltd Stable Compositions comprising Linaclotide
JP2018516937A (ja) * 2015-06-05 2018-06-28 アイアンウッド ファーマシューティカルズ インコーポレイテッド リナクロチドの改変または標的放出製剤
EP3359181A1 (en) 2015-10-07 2018-08-15 Cyprumed GmbH Pharmaceutical formulations for the oral delivery of peptide drugs
TWI795462B (zh) * 2017-11-17 2023-03-11 日商鹽野義製藥股份有限公司 光安定性及溶出性優異的醫藥製劑
CN116098864B (zh) * 2023-04-11 2023-06-09 北京普诺旺康医药科技有限公司 一种利那洛肽干混悬剂及其制备方法

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH658973A5 (fr) * 1983-12-29 1986-12-31 Nestle Sa Produit aromatisant.
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
JPS63146828A (ja) * 1986-07-18 1988-06-18 Chugai Pharmaceut Co Ltd 安定な顆粒球コロニ−刺激因子含有製剤
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
JPS649938A (en) 1987-06-30 1989-01-13 Agency Ind Science Techn Oral ingestive composition
JPH03505334A (ja) 1989-04-11 1991-11-21 イミユノバイオロジー・リサーチ・インスチチユート・インコーポレーテツド 凍結乾燥されたペプチド製剤
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
US5221495A (en) * 1990-04-13 1993-06-22 Colgate-Palmolive Company Enzyme stabilizing composition and stabilized enzyme containing built detergent compositions
US5451410A (en) 1993-04-22 1995-09-19 Emisphere Technologies, Inc. Modified amino acids for encapsulating active agents
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5654278A (en) * 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
US5593696A (en) * 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
ZA965368B (en) * 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
RU2203085C2 (ru) 1996-07-03 2003-04-27 Элзэ Копэрейшн Стабильный неводный препарат пептидного соединения, способ его получения и способ лечения гормон-зависимого заболевания у субъекта
US5916582A (en) 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
US5932547A (en) 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
US6087478A (en) * 1998-01-23 2000-07-11 The Rockefeller University Crystal of the N-terminal domain of a STAT protein and methods of use thereof
AU5026599A (en) 1998-07-23 2000-02-14 Novo Nordisk A/S A wet granulation method for preparing a stable pharmaceutical formulation
DE69921353T2 (de) 1998-11-27 2005-11-10 Kanji Takada Oral anzuwendendes arzneimittel zur wirkstoffverabreichung im magendarmtrakt
AU2001220765A1 (en) 2000-01-24 2001-07-31 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
JP2004501191A (ja) * 2000-06-28 2004-01-15 テバ ファーマシューティカル インダストリーズ リミティド カルベジロール
FR2811884B1 (fr) 2000-07-21 2003-01-31 Oreal Utilisation en cosmetique de betainates d'amidon et composition les comprenant associes a au moins un agent benefique pour les matieres keratiniques
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
WO2002026248A1 (en) 2000-09-29 2002-04-04 Cognetix, Inc. Stable peptide formulations
DE60127175T2 (de) 2000-12-21 2007-11-08 Nektar Therapeutics, San Carlos Lagerstabile pulverzusammensetzungen mit interleukin-4 rezeptor
CA2435835A1 (en) 2001-02-02 2002-08-15 Pharmacia Corporation Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
GB0104371D0 (en) * 2001-02-22 2001-04-11 Clariant Int Ltd Color improving stabilizing compositions comprising leucine
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
CN103641892B (zh) * 2001-03-29 2015-06-17 药物协和公司 用于治疗组织炎症和癌变的鸟苷酸环化酶受体激动剂
AU2002355542A1 (en) 2001-08-09 2003-02-24 Doctor's Signature Sales And Marketing International Corp. ((Dba)) Life Force International Protonic formulation
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
EP1458407A1 (en) * 2001-12-21 2004-09-22 Novo Nordisk A/S Liquid composition of modified factor vii polypeptides
JP2003201256A (ja) 2001-12-28 2003-07-18 Hisamitsu Pharmaceut Co Inc 大腸送達性経口医薬製剤、大腸癌治療用経口医薬製剤および大腸炎治療用経口医薬製剤
DE10261126A1 (de) * 2002-08-13 2004-03-04 Aventis Behring Gmbh Lagerungsstabile, flüssige Fibrinogen-Formulierung
KR20050088311A (ko) 2002-12-11 2005-09-05 화이자 프로덕츠 인크. 고지방 환경 내로의 활성 물질의 조절-방출
US7371727B2 (en) * 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2 (en) * 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
SG168407A1 (en) * 2003-01-28 2011-02-28 Ironwood Pharmaceuticals Inc Methods and compositions for the treatment of gastrointestinal disorders
JP4353982B2 (ja) * 2003-05-14 2009-10-28 インダス バイオテック ピーブイティ. エルティーディー. 糖尿病処置用相乗作用組成物
BRPI0411114B8 (pt) * 2003-06-10 2021-05-25 Lg Chemical Ltd solução aquosa estável de eritropoetina humana, não contendo albumina de soro
PL1644021T3 (pl) 2003-06-13 2013-01-31 Ironwood Pharmaceuticals Inc Sposoby i kompozycje do leczenia zaburzeń żołądkowo-jelitowych
US7494979B2 (en) 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
KR100560697B1 (ko) 2003-08-06 2006-03-16 씨제이 주식회사 알부민을 함유하지 않는 에리스로포이에틴 제제
DE202004020676U1 (de) * 2004-03-10 2005-11-10 Bioceuticals Arzneimittel Ag Erythropoietin-Flüssigformulierung
JP4744533B2 (ja) 2004-12-30 2011-08-10 ドゥビエル カンパニー リミテッド 噴霧乾燥高分子型コレクチン属タンパク質及びその製造方法
EP1940441A4 (en) * 2005-08-19 2010-01-27 Ironwood Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR TREATING GASTROINTESTINAL DISORDERS
WO2007044375A2 (en) 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
JP2009527504A (ja) * 2006-02-23 2009-07-30 イオメディックス スリープ インターナショナル エスアールエル 良質な睡眠の誘導および維持のための組成物および方法
CA2652677A1 (en) * 2006-02-24 2007-09-07 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ITMI20060629A1 (it) * 2006-03-31 2007-10-01 Daniele Giovannone Composizioni solide orali a base di s-adenosilmetionina e processo per il loro ottenimento
US7960339B2 (en) 2006-07-10 2011-06-14 Österreichische Akademie der Wissenschaften Antimicrobial peptides
EP2049081B1 (en) 2006-08-09 2012-11-14 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
AU2007289344B2 (en) 2006-08-31 2011-04-14 Novartis Ag Pharmaceutical compositions comprising hGH for oral delivery
WO2008078189A2 (en) * 2006-12-20 2008-07-03 Bayer Healthcare Llc Factor vii and viia compositions
US8779090B2 (en) 2007-02-26 2014-07-15 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of heart failure and other disorders
GB0710321D0 (en) * 2007-05-30 2007-07-11 Nhs Blood & Transplant Method
EP2527360B1 (en) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CN117530912A (zh) * 2008-08-15 2024-02-09 硬木药品公司 适合口服给药的鸟苷酸环化酶-c受体激动剂多肽的稳定的固体制剂
US20120039949A1 (en) * 2008-09-04 2012-02-16 Ironwood Pharmaceuticals, Inc. Stable Solid Formulations of GC-C Receptor Agonist Polypeptides Suitable for Oral Administration
US20120009225A1 (en) * 2008-09-04 2012-01-12 Ironwood Pharmaceuticals, Inc. Stable Solid Formulation of Therapeutic Polypeptides Suitable for Oral Administration
CA2994066A1 (en) 2008-12-03 2010-06-10 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
CA2770077A1 (en) 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
CA2770334A1 (en) * 2009-08-12 2011-02-17 Forest Laboratories Holdings Limited Orally disintegrating compositions of linaclotide

Similar Documents

Publication Publication Date Title
JP2013501071A5 (https=)
JP2013535505A5 (https=)
JP7262774B2 (ja) 治療剤送達のための血小板組成物及び方法
JP2014525429A5 (https=)
US11833255B2 (en) Nanoparticles with pH triggered drug release
US20180105430A1 (en) Generation of mesoporous materials using multiphase surfactant systems
JP2015508774A5 (https=)
US9572864B2 (en) Compositions and uses of lectins
JP2012512907A5 (https=)
HRP20140807T1 (hr) Derivati pirolo[2,3-d]pirimidina kao inhibitori protein kinaze b
WO2015042268A1 (en) Core and surface modification of mesoporous silica nanoparticles to achieve cell specific targeting in vivo
JP2019504086A5 (https=)
JP2008533007A5 (https=)
NZ608502A (en) Polypeptides that bind to human complement component c5
EP2981249A1 (en) Mesoporous alum nanoparticles as universal platform for antigen adsorption, presentation, and delivery
JP2013510169A5 (https=)
RU2734930C2 (ru) Режимы дозирования мелфлуфена для раковых заболеваний
CA3019769C (en) Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
JP2017532316A5 (https=)
WO2024131833A1 (en) Mrna-based hpv+ cancer vaccines, and uses thereof
JP2011510667A5 (https=)
US20230226211A1 (en) Cd25-targeted il-2 for increasing cd4 t cell formation and treatment of infections
JP2013503148A5 (https=)
WO2005067975A1 (fr) Formulation de captopril a liberation continue possedant une structure d'intercalation supramoleculaire et procede de fabrication correspondant
JP2008514561A5 (https=)